Withus Pharmaceutical위더스제약
330350 · KOSDAQ · ₩330350 · 위더스제약
₩6,450▲ ₩50 (0.78%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩106B | ₩103B | ₩80B | ₩65B | ₩57B |
| Cost of sales | ₩38B | ₩37B | ₩31B | ₩26B | ₩24B |
| Gross profit | ₩69B | ₩66B | ₩49B | ₩38B | ₩34B |
| Operating income | ₩5.7B | ₩5.7B | ₩7.9B | ₩4.9B | ₩4.9B |
| Net income | ₩5B | ₩4.8B | ₩8B | ₩2.5B | ₩4.3B |
| Net income to shareholders | ₩5B | ₩4.8B | ₩8B | ₩2.5B | ₩4.3B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩137B | ₩135B | ₩131B | ₩119B | ₩119B |
| Current assets | ₩68B | ₩61B | ₩58B | ₩59B | ₩76B |
| Cash and equivalents | ₩17B | ₩18B | ₩9.2B | ₩9B | ₩14B |
| Total liabilities | ₩39B | ₩42B | ₩41B | ₩36B | ₩38B |
| Current liabilities | ₩33B | ₩34B | ₩31B | ₩26B | ₩24B |
| Borrowings | ₩18B | ₩24B | ₩19B | ₩21B | ₩23B |
| Total equity | ₩98B | ₩93B | ₩90B | ₩83B | ₩81B |
| Shareholders' equity | ₩98B | ₩93B | ₩90B | ₩83B | ₩81B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩6.8B | ₩9.6B | −₩1.2B | ₩5.4B | ₩8B |
| Capital spending | ₩1.3B | ₩2.4B | ₩11B | ₩15B | ₩6.7B |
| Free cash flow | ₩5.5B | ₩7.3B | −₩12B | −₩10B | ₩1.4B |
| Dividends paid | ₩0 | ₩1.3B | ₩0 | ₩633M | ₩422M |
Consolidated where available. Amounts in won.
Also known as: Withus Pharmaceutical / 위더스제약 / 330350 / KRX:330350
Source: KRX statistical information